STUDY OF LIPOPROTEIN A, LIPID PROFILE AND LIPOPROTEIN LIPASE IN TYPE 2 NON INSULIN DEPENDENT DIABETES MELLITUS

Abstract

Type 2 diabetes mellitus is often characterized by hyperglycemia as a result of increased insulin resistance in hepatic, peripheral tissues and pancreatic ?-cell dysfunction. Approximately 92% of patients with type 2 diabetes mellitus demonstrate insulin resistance; however hyperglycemia is always a consequence of insulin deficiency. This study was done on 150 patients newly diagnosed diabetes type 2 characterized by dyslipidaemia that is increased triglycerides and decreased HDL. Hypoglycemia and weight gain are common problems with oral sulfonylurea drugs. In this study two different oral hypoglycemic drugs Glibenclamide (insulin secretagogues) and Pioglitazone (insulin sensitizer) were used for treatment of patients with type 2 diabetes mellitus. The effects of these drugs lipid profiles (TC, TG, and HDL) lipoprotein and lipoprotein lipase were studied. Two groups of newly diagnosed type 2 diabetic patients, group 1 (75 patients) were subjected to treatment with Glibenclamide (5 mg once daily), group 2, (75patients) were subjected to treatment with Pioglitazone (15mg twice daily). Lipid profiles (TC, TG, and HDL) and Lipoprotein a, lipoprotein lipase were analysed for these patients before and after 90 days of oral hypoglycemic drug treatment. The results demonstrated that Glibenclamide has a greater postprandial glucose regulator effect than Pioglitazone. In addition the hypoglycemic episode and weight gain were less in patients treated Glibenclamide with than those treated with Pioglitazone. Glibenclamide produces greater percent reduction with respect to fasting blood glucose levels, postprandial blood glucose levels compared to Pioglitazone.

Key words: Lipoprotein a,  lipoprotein lipase, Coronary artery disease, Oral hypoglycemic drugs, Glibenclamide, Pioglitazone, Type 2 diabetes mellitus